These therapies are designed to bind specifically to receptors or biological targets, thereby ensuring a more directed and effective treatment while reducing systemic exposure and unintended side-effects.
Two of the leading targeted modalities, antibody drug conjugates (ADCs) and targeted protein degraders (TPDs), are poised to experience significant market growth in the future.
The ADC market, for instance, is projected to increase from $7.6 billion in 2022 to $19.8 billion by 2028, growing at a CAGR of 15.2% during that period.1
Similarly, the global TPD market was valued at approximately $541.98 million in 2024 and is expected to reach $3.55 billion by 2034, growing at a CAGR of 20.7% during the forecast period.2
Although targeted modalities are most commonly associated with oncology, their application is expanding into other disease states where specific pathways can be leveraged for therapeutic intervention.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.